BURLINGTON, Mass., Nov. 12, 2014 /PRNewswire/ -- Decision Resources Group finds that the ulcerative colitis (UC) market will grow over the next decade from $2.7 billion in 2013 to $4.2 billion in 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan. Expanded use of tumor necrosis factor (TNF)-alpha inhibitors for maintenance and uptake of emerging therapies as alternatives for the anti-TNFs will be the primary drivers of growth during this period. Sales of biologics will contribute approximately $2.3 billion to the UC market in 2023.
Other key findings from the Pharmacor report entitled Ulcerative Colitis:
- Current therapies and medical practice: Conventional therapies (i.e., aminosalicylates and corticosteroids) will remain entrenched as first-line therapies for most UC patients, followed by immunosuppressants and/or biologics as second- and third-line treatments.
- TNF-alpha inhibitors patient share: Janssen/Merck/Mitsubishi Tanabe's Remicade will likely remain the preferred biologic for moderate to severe UC; however, Remicade will face competition from the subcutaneous TNF-alpha inhibitors Humira (AbbVie/Eisai) and Simponi (Janssen/Merck/Mitsubishi Tanabe) as patient preference for these conveniently delivered agents grows.
- Newly launched and emerging therapies: Uptake of Takeda's cell adhesion molecule inhibitor Entyvio, beginning in 2014, and entry of Pfizer's Jak inhibitor Xeljanz in the second half of the forecast period will increase market sales, offering alternative lines of therapy to the TNF-alpha inhibitors.
Comments from Decision Resources Group Analyst Adi Reske, Ph.D.:
- "Given the unmet need for efficacious therapies and additional pharmacological options for moderate to severe UC, emerging agents that offer novel mechanisms of action will be a welcome addition to the UC treatment algorithm; however, reimbursement restrictions imposed by third-party payers will continue to prevent greater penetration of high-priced biologics into the drug-treated UC population."
- "Entry of biosimilar TNF-alpha inhibitors at a discounted price to the branded version, will constrain the UC market. Competition between branded and biosimilar TNF-alpha inhibitors and payer pressure to use the biosimilars will likely contribute to notable erosion of TNF-alpha inhibitor brand sales."
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
SOURCE Decision Resources Group